2-1-1 Nihonbashi-Muromachi
Chuo 103-8324
Japan
81 3 3281 6611
https://www.chugai-pharm.co.jp
Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 7,604
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Osamu Okuda | President, CEO & Representative Director | 1.4M | N/A | 1963 |
Toshiya Sasai | Executive of Investor Relations Group & Corporate Communications Department | N/A | N/A | N/A |
Mr. Masayoshi Higuchi | VP and Head of Quality, Regulatory Compliance Unit, Business Strategy & Compliance Dept. | N/A | N/A | N/A |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Chugai Pharmaceutical Co., Ltd.’s ISS governance QualityScore as of 1 May 2024 is 5. The pillar scores are Audit: 1; Board: 7; Shareholder rights: 2; Compensation: 1.